Difference between revisions of "Abdelwahab 2018 Oncogene"
| Line 12: | Line 12: | ||
|diseases=Other | |diseases=Other | ||
|organism=Human | |organism=Human | ||
|tissues=Lung;gill | |tissues=Lung;gill, Endothelial;epithelial;mesothelial cell | ||
|preparations=Intact cells | |preparations=Intact cells | ||
|couplingstates=ROUTINE | |||
|pathways=ROX | |pathways=ROX | ||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
|additional= | |additional=2019-01, | ||
}} | }} | ||
Latest revision as of 12:32, 9 August 2019
| Abdelwahab EMM, Pal S, Kvell K, Sarosi V, Bai P, Rue R, Krymskaya V, McPhail D, Porter A, Pongracz JE (2018) Mitochondrial dysfunction is a key determinant of the rare disease lymphangioleiomyomatosis and provides a novel therapeutic target. Oncogene 38:3093-3101. |
Abdelwahab EMM, Pal S, Kvell K, Sarosi V, Bai P, Rue R, Krymskaya V, McPhail D, Porter A, Pongracz JE (2018) Oncogene
Abstract: Lymphangioleiomyomatosis (LAM) is a rare and progressive systemic disease affecting mainly young women of childbearing age. A deterioration in lung function is driven by neoplastic growth of atypical smooth muscle-like LAM cells in the pulmonary interstitial space that leads to cystic lung destruction and spontaneous pneumothoraces. Therapeutic options for preventing disease progression are limited and often end with lung transplantation temporarily delaying an inevitable decline. To identify new therapeutic strategies for this crippling orphan disease, we have performed array based and metabolic molecular analysis on patient-derived cell lines. Our results point to the conclusion that mitochondrial biogenesis and mitochondrial dysfunction in LAM cells provide a novel target for treatment.
• Bioblast editor: Plangger M
Labels: MiParea: Respiration, mtDNA;mt-genetics, nDNA;cell genetics, Pharmacology;toxicology
Pathology: Other
Organism: Human Tissue;cell: Lung;gill, Endothelial;epithelial;mesothelial cell Preparation: Intact cells
Coupling state: ROUTINE
Pathway: ROX
HRR: Oxygraph-2k
2019-01
